Navigation Links
Capsule in Medical Technology

American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule

... a phase one clinical trial of AOBO-001, an oral capsule developed from traditional Chinese ... currently manufactures and markets the oral capsule in China under the Cease Enuresis Oral capsule brand, which was approved by China's State Food ...

Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997

... (DLTs) for the agent when administered orally in capsule form every two weeks to patients with a diverse ... CYT997 given as an oral capsule every two ... CYT997 given as an oral capsule dose. ...

Mayo Clinic Finds Capsule Endoscopy Can Detect Intestinal Damage Caused by Celiac Disease

... -- Mayo Clinic researchers have found that capsule endoscopy can provide a magnified view of the ... and a gastroenterologist at Mayo Clinic. The capsule is approximately the size of a large vitamin, and ... hours to move through the small intestine. As the capsule moves through the digestive tract, images ...

Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule

... to evaluate the safety, tolerability and efficacy of its oral insulin capsule ORMD-0801. OnQ Consulting, a clinical research organization (CRO) located ... through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's ...

Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics

... trial is focused on assessing the safety and efficacy of its oral insulin capsule on nine Type 1 diabetes patients. The start of this clinical trial on ... serious adverse events. "The commencement of trials of our oral insulin capsule on Type 1 diabetics signals another major step forward for our company in ...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

... with results previously presented with twice-daily dosing of the capsule formulation in the same study. All dosing regimens tested in the study ... tablet formulation, and patients receiving 400 mg twice daily with the capsule formulation, experienced a 1.8 - 1.9 log median reduction in plasma viral ...

Anti-Cancer Drug CYT997 Update

... intravenous administration -- continued dose-escalation in its Phase I capsule dosing study (oral administration) Phase II clinical programs 1. ... and clinical activities. Phase I clinical program 1. Phase I capsule clinical study Cytopia has continued to accelerate dose-escalation in ...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results

... address issues and or requests set forth in the December 12, 2007 indiplon capsule action letter from the FDA in a timely manner if at all; risk that the ... address issues and or requests set forth in the December 12, 2007 indiplon capsule action letter from the FDA in a manner acceptable to the FDA if at all; ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... AEROLIZER should not be used to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Do not use more than one capsule twice daily. FORADIL AEROLIZER should be used with caution in patients with cardiovascular disorders. FORADIL AEROLIZER is not a substitute for ...

Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009

... via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... gastrointestinal system. About Traficet-EN(TM) (CCX282-B) Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 ...

BIOCOM's 4th Annual DeviceFest Honors Companies

... to provide a unique safety solution to prevent accidental needlestick injuries. "The Far Out" award went to CVAC Systems, Inc for its unique capsule device focused on the application of its Cyclic Variations in Altitude Conditioning process to treat diseases and disorders associated with aging, ...

New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus

... increases in T-cell production of TNF-alpha, a key immune marker, versus control upon exposure to influenza A in healthy adults who consumed a daily capsule of Bacillus coagulans GBI-30, PTA-6086 for 30 days. While many health professionals believe that probiotics can help people who have specific ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... sample packs to clearly demonstrate the rapid relief and tolerability of RAPAFLO(TM)." The product label provides that one 8 mg RAPAFLO(TM) capsule be taken once daily with a meal. Stocking efforts have ensured the product will be available immediately by prescription at retail pharmacies ...

B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase

... and Outlook(R) Safety Infusion Systems using two-way communication with numerous vendors including Cerner, GE Centricity, Draeger, Philips, capsule and more. "We look forward to the opportunity to interact with other healthcare professionals and demonstrate our solutions in the kind of ...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

... with our colleagues," said Nadav Kidron, Oramed CEO. "As we indicated at the completion of the study, the trial demonstrated that the oral insulin capsule had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes." Oramed's ...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

... However, OGD proposes without explanation that a Q1Q2 standard developed for oral solutions will nonetheless apply to Vancocin, an oral capsule product. Then, OGD backs off the sameness supposedly ensured by the Q1Q2 standard, and permits generic applicants to vary their inactive ingredients ...

Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss

... B6, B12, and folic acid, can address deficiencies in these nutrients associated with eye problems, including dry eye and macular health." Each capsule of Animi-3 contains 500 mg of omega-3, (350 mg of DHA), 200 mg of phytosterols, 1 mg of folic acid, 12.5 mg of B6, and 12 mcg of B12. More ...

Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository

... via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at ...

US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream

... of muscle tissue damage due to lactic acid build up. Glyc'n Go(TM) delivers more pure GlycoCarn(R) per serving than any other GPLC tablet or capsule on the market today. Glyc'n Go(TM) is the only chewable form of GlycoCarn(R) and has been proven to dissolve 26% faster than tablets, enabling the ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... TEMODAR Capsules should not be opened or chewed. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. The effectiveness of TEMODAR in children has not been ...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

... in 5-15% of subjects in clinical studies with Durezol included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1-5% ...

Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)

... in 5-15% of subjects in clinical studies with Durezol included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1-5% ...

Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain

... in 5-15% of subjects in clinical studies with Durezol included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1-5% ...

Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

... days. A total of 60 patients have been randomised for this study. The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with IV vancomycin in the treatment of cSSSI. The primary endpoint is the clinical cure ...

Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform

... via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at ...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

... ALO-01 capsules for priority review. The priority review status provides for a review period of six months from the date of submission. The ALO-01 capsule NDA was submitted on June 30, 2008. In the United States, pain is a serious, undertreated public health problem, with 19 percent of American adults ...

Cytopia Commences Second Phase II Study in Brain Cancer

... administered by mouth. Preliminary data from the company's Phase I oral study indicates that the compound is well absorbed after administration in capsule form. This key finding differentiates CYT997 from other vascular disrupting agents currently in development which can only be administered ...

REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted

... for moderate-to-severe chronic pain. About ORADUR(TM) Technology ORADUR is a proprietary technology designed to transform short-acting oral capsule dosage forms into sustained release oral products, with the added benefit of being less prone to abuse (e.g. by crushing or water extraction) than ...

Scientists Reveal Roadmap to Brain Health That Can Be Passed Down to Future Generations: Exercise, Omega-3, Folic Acid, Vitamin B6, and Vitamin B12

... particular interest here is the effect addressing deficiencies in DHA may have on brain health as well as the brains of future generations." Each capsule of Animi-3 contains 500 mg of omega-3, (350 mg of DHA), 1 mg of folic acid, 12.5 mg of B6, and 12 mcg of B12. For more information, visit ....

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

... in chemokine-based therapeutics." About CCX282-B (Traficet-EN(TM)) Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which controls the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. ...

Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

... Infections (cSSSI). Enrolment remains on track for completion in 2008. The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with a full course of intravenous (i.v.) treatment with vancomycin in the treatment of ...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

... Doses in Patients with PAH, Dr. R. James White of the University of Rochester presented data from a 12-patient study showing that a sustained-release capsule of treprostinil administered twice daily allowed patients to maintain consistent therapeutic levels of treprostinil in their bloodstreams in an ...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

... an extended-release opioid, morphine sulfate, with a sequestered core of naltrexone, an opioid antagonist, which is designed to be released if the capsule is tampered with by crushing, chewing or dissolving, thereby significantly reducing the euphoric effect of the opioid. According to Phase I study ...

Pregnant Women Need Omega-3 to Boost Infant Development

... President Jack Schramm. "The DHA in Animi-3 is all natural and purified to eliminate any contaminants including those commonly found in fish." Each capsule of Animi-3 contains 500 mg of omega-3 acids, including 350 mg of DHA. For more information, visit http://www.animi-3.com . *docosahexaenoic acid ...

InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update

... HCV compounds of different mechanisms of action. In the Phase 1b study, four cohorts of treatment-nave patients received ITMN-191 in a gelatin capsule every 12 hours or every 8 hours with food for a period of 14 days. In addition, a single cohort of treatment-experienced chronic hepatitis C patients ...

Diagnostic Center for Disease: Prostate Biopsy Spreads Prostate Cancer Cells

... cancer cells beyond the prostate when a biopsy is performed. An extensive review of the literature confirms that once a needle penetrates the capsule of an organ, a phenomenon called "needle tracking" takes place. When the needle is withdrawn from the targeted organ, the chance of spreading cancer ...

Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168

... dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole) to ...

Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout

... exposure-dependent reduction in serum uric acid (SUA). In the dose group that resulted in the highest plasma drug levels (400 mg modified-release capsule twice daily), there was a 50.9% placebo-adjusted reduction in SUA (p < 0.001). The following table summarizes the results by dose group. Effect ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... in enthesitis and dactylitis, two common disease manifestations causing pain and swelling. Enthesitis, an inflammation of a tendon, ligament or joint capsule insertion to the bone and dactylitis, a swelling of digits in the hands or feet, are estimated to affect more than one-third of people with psoriatic ...
Other Contents
(Date:4/17/2014)... 16, 2014. Kessler Foundation has been named awardee ... the Department of Defense Spinal Cord Injury Research ... for the randomized, double-blinded, controlled, multi-site clinical trial, ... muscle strength after spinal cord injury. Dr. Forrest ... Research at Kessler Foundation. Two additional sites will ...
(Date:4/17/2014)... This news release is available in German . ... enable us to recognise objects; they also provide us with ... we run, turn around, fall or sit still in a ... characteristic motion trace on our retinas. Seemingly without effort, our ... can maintain a stable position and a steady gaze during ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
Other TagsOther Tags